Compare Sanofi SA (SNY) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Advanced Drainage Systems Inc — how do they compare? Sanofi SA trades at $43.12 (market cap $104.06B), while Advanced Drainage Systems Inc trades at $131.78 (market cap $10.08B). The key difference: Sanofi SA is far larger — about 10.3× Advanced Drainage Systems Inc's market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| SNY | WMS | |
|---|---|---|
Market Cap | $104.06B | $10.08B |
Sector | Health | Industrials |
52-Week High | $52.34 | $175.38 |
52-Week Low | $41.33 | $129.50 |
Enterprise Value | $124.09B | $11.68B |
Dividend Yield | 5.61% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Advanced Drainage Systems (WMS) trades at $133.67, down 1.54% on the day, amid a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.49 exceeding the $2.10 forecast. Revenue for 2025 was $2.90 billion, with a net income margin of 15.5%. Analyst consensus is a Buy with a $188.20 price target, though technical indicators show selling pressure. Recent news highlights institutional buying and strong Q1 2027 results.
The outlook for WMS is mixed; strong fundamentals and analyst optimism contrast with near-term technical weakness. Investment opportunities include market share gains and acquisition synergies, while risks involve cyclical construction exposure and rising investing cash outflows. The stock's current price offers a potential upside to the consensus target, but investors should weigh execution risks against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
